And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to escort Mrs. Pharmalot to a rent party, catch up on our growing pile of books, and promenade with our official mascot. And what about you? This is a fine time to catch up with someone special, whittle down your own reading list, do some binge-watching, or you could plan a spring season getaway. Or maybe you want to store provisions in the event of another U.S. government shutdown. Well, whatever you do, have a grand time. but be safe. Enjoy, and see you soon …

The Trump administration has been trumpeting a huge increase in generic drug approvals the past two years, but nearly half of those newly approved medicines are not being sold in the U.S., Kaiser Health News reveals. More than 700, or about 43 percent, of the generics were not on the market as of early January. Notably, 36 percent of the generics that would be the first to compete against a branded drug are not yet for sale. “It’s a real problem because we’re not getting all the expected competition,” says FDA Commissioner Scott Gottlieb.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy